CSL (OTCMKTS:CSLLY) Stock Price Up 6.3% – Here’s Why

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) was up 6.3% on Wednesday . The company traded as high as $18.19 and last traded at $18.15. Approximately 4,274 shares traded hands during trading, a decline of 99% from the average daily volume of 448,426 shares. The stock had previously closed at $17.08.

Analyst Upgrades and Downgrades

Several research firms have issued reports on CSLLY. Zacks Research lowered CSL from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th. Citigroup lowered CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Royal Bank Of Canada lowered CSL from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, February 11th. Jefferies Financial Group lowered CSL from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 29th. Finally, Canaccord Genuity Group lowered CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

CSL Trading Up 3.7%

The company has a 50 day moving average of $21.00 and a two-hundred day moving average of $40.66. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 2.57.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.